Predicting Antibody Neutralization Efficacy in Hypermutated Epitopes Using Monte Carlo Simulations

Area of Science:

• Immunology
• Virology
• Computational Biology

Background:

• Human Immunodeficiency Virus 1 (HIV-1) rapidly mutates its envelope glycoprotein, evading immune responses and antibody neutralization.
• Broadly neutralizing antibodies (bNAbs) show promise for HIV-1 therapy but their efficacy varies due to viral resistance.
• Distinguishing between antibody-sensitive and resistant HIV-1 strains is essential for optimizing antibody treatments.

Purpose of the Study:

• To develop a method for predicting the neutralization efficacy of bNAbs against different HIV-1 isolates.
• To investigate the binding characteristics of HIV-1 strains in relation to bNAb sensitivity.
• To aid in the design of improved bNAbs and personalized antibody-based HIV therapies.

Main Methods:

• Utilized Protein Energy Landscape Exploration (PELE), a Monte Carlo simulation method.
• Simulated the three-dimensional binding interactions between the HIV-1 gp120 envelope protein and three anti-CD4bs bNAbs (VRC01, NIH45-46, 3BNC117).
• Analyzed binding profiles to identify differences between sensitive and resistant viral strains.

Main Results:

• Identified distinct binding profiles for HIV-1 strains sensitive versus resistant to bNAbs.
• Observed weaker binding interactions in resistant viral strains compared to sensitive strains.
• Demonstrated the potential of binding profile analysis for predicting antibody neutralization efficacy.

Conclusions:

• Computational simulation of binding interactions can effectively discriminate between HIV-1 strains with varying sensitivity to bNAbs.
• Differences in binding profiles provide a basis for predicting antibody efficacy against hypermutated HIV-1.
• This approach can inform the development of more potent bNAbs and guide clinical antibody treatment strategies.